Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-18 Sale | 2024-11-19 4:31 pm | Revance Therapeutics Inc. | RVNC | Hollander David CMO & Global Therapeutics Lead | 3,908 | $4.17 | $16,296 | 104,945 (Direct) | View |
| 2024-04-16 Sale | 2024-04-17 4:34 pm | Revance Therapeutics Inc. | RVNC | Jordan Erica Chief Commercial Officer | 2,392 | $3.8028 | $9,096 | 114,864 (Direct) | View |
| 2024-03-18 Sale | 2024-03-19 6:45 pm | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 9,211 | $5.0425 | $46,446 | 167,550 (Direct) | View |
| 2024-03-18 Sale | 2024-03-19 6:44 pm | Revance Therapeutics Inc. | RVNC | Moxie Dwight CLO & GC | 8,125 | $5.0426 | $40,971 | 137,815 (Direct) | View |
| 2024-03-18 Sale | 2024-03-19 6:44 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 9,361 | $5.0426 | $47,204 | 192,666 (Direct) | View |
| 2024-03-06 Purchase | 2024-03-08 4:33 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 30,000 | $6.98 | $209,400 | 1,126,381 (Indirect Direct) | View |
| 2023-09-05 Sale | 2023-09-07 5:37 pm | Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary | 34,853 | $17.58 | $612,624 | 44,066 (Direct) | View |
| 2023-08-03 Sale | 2023-08-04 5:07 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 26,279 | $22.57 | $593,151 | 951,288 (Indirect Direct) | View |
| 2023-07-03 Sale | 2023-07-05 9:11 pm | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,701 | $25.04 | $42,593 | 79,896 (Direct) | View |
| 2023-07-03 Sale | 2023-07-05 9:11 pm | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 26,279 | $24.94 | $655,333 | 977,567 (Indirect Direct) | View |
| 2023-06-15 Sale | 2023-06-20 4:25 pm | Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director | 2,500 | $28.24 | $70,600 | 24,817 (Direct) | View |
| 2023-06-09 Sale | 2023-06-13 8:09 pm | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 5,000 | $30.82 | $154,096 | 147,347 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-30 Option Award | 2024-07-02 5:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,000 | $2.1845 | 1,106,848 (Direct) | View |
| 2024-06-30 Option Award | 2024-07-02 5:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 1,000 | $2.1845 | 193,666 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:47 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Ware Olivia C Director | 38,458 | $0 | 55,133 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:47 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Russell Angus C. Director | 38,458 | $0 | 74,964 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:46 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Nolet Chris Director | 38,458 | $0 | 67,064 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:45 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director | 38,458 | $0 | 55,019 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:44 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Gangolli Julian S Director | 38,458 | $0 | 68,564 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:43 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Coric Vlad Director | 38,458 | $0 | 44,242 (Direct) | View |
| 2024-05-01 Option Award | 2024-05-03 08:42 am | N/A 2034-04-30 | Revance Therapeutics Inc. | RVNC | Beraud Jill Director | 38,458 | $0 | 67,064 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:45 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 2,967 | $5.305 | 167,550 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:44 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Moxie Dwight CLO & GC | 3,269 | $5.305 | 137,815 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:44 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 3,822 | $5.305 | 192,666 (Direct) | View |
| 2024-03-15 Tax Withholding | 2024-03-19 6:43 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 20,533 | $5.305 | 1,105,848 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 5:34 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 22,110 | $0 | 179,728 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 5:33 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Moxie Dwight CLO & GC | 15,143 | $0 | 149,209 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 4:44 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 17,447 | $0 | 205,849 (Direct) | View |
| 2024-02-29 Option Award | 2024-03-04 4:33 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 70,750 | $0 | 1,096,381 (Direct) | View |
Ownership | 2024-02-29 4:36 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Jordan Erica Chief Commercial Officer | 0 | $0 | 237,256 (Direct) | View |
Ownership | 2024-02-29 4:32 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Hollander David CMO & Global Therapeutics Lead | 0 | $0 | 278,522 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 4:48 pm | 2025-02-15 2028-01-31 | Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary | 225,000 | $0 | 269,066 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 4:46 pm | 2025-02-15 2028-01-31 | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 241,668 | $0 | 333,403 (Direct) | View |
| 2024-01-31 Option Award | 2024-02-02 4:45 pm | 2025-02-15 2028-01-31 | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,070,001 | $0 | 1,070,001 (Direct) | View |
| 2023-12-31 Option Award | 2024-01-03 4:50 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 264 | $7.47 | 157,618 (Direct) | View |
| 2023-12-31 Option Award | 2024-01-03 4:48 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 434 | $7.47 | 91,735 (Direct) | View |
| 2023-12-31 Option Award | 2024-01-03 4:47 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 264 | $7.47 | 1,025,631 (Direct) | View |
| 2023-12-15 Tax Withholding | 2023-12-18 4:32 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 4,712 | $8.08 | 157,354 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:16 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 11,215 | $18.91 | 91,301 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:16 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 22,620 | $0 | 91,301 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary | 9,592 | $18.91 | 78,919 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Moxie Dwight SVP, GC & Secretary | 19,346 | $0 | 78,919 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 8,901 | $18.91 | 162,066 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 22,620 | $0 | 162,066 (Direct) | View |
| 2023-08-11 Tax Withholding | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 48,064 | $18.91 | 1,025,367 (Direct) | View |
| 2023-08-11 Option Award | 2023-08-15 4:15 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 122,143 | $0 | 1,025,367 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 9:11 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Schilke Tobin CFO | 769 | $15.61 | 79,896 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 9:11 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Sjuts Dustin S President | 1,000 | $15.61 | 148,347 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 9:11 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Foley Mark J CEO | 1,000 | $15.61 | 977,567 (Direct) | View |
| 2023-06-15 Exercise | 2023-06-20 4:25 pm | N/A 2032-05-03 | Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director | 2,500 | $0 | 24,817 (Direct) | View |
| 2023-06-15 Exercise | 2023-06-20 4:25 pm | N/A N/A | Revance Therapeutics Inc. | RVNC | Kolaja Carey OConnor Director | 2,500 | $18.12 | 24,817 (Direct) | View |